Valuation: Onconic Therapeutics Inc.

Market Cap 549B 409M 367M 338M 307M 581M 38.33B 597M 4.05B 1.61B 20.53B 1.53B 1.5B 64.92B P/E 2024
-16.5x
P/E 2025 56.2x
Enterprise Value 497B 370M 332M 306M 277M 525M 34.66B 540M 3.66B 1.46B 18.57B 1.39B 1.36B 58.7B EV / Sales 2024
9.02x
EV / Sales 2025 15.3x
Free-Float
50.62%
Yield 2024 *
-
Yield 2025 -
1 day+4.22%
1 week+2.54%
Current month-0.08%
1 month-18.63%
3 months-17.52%
6 months-40.69%
Current year-38.11%
1 week 11,100
Extreme 11100
12,800
1 month 11,100
Extreme 11100
15,170
Current year 8,790
Extreme 8790
28,900
1 year 8,790
Extreme 8790
28,900
3 years 3,137.5
Extreme 3137.5
28,900
5 years 3,137.5
Extreme 3137.5
28,900
10 years 3,137.5
Extreme 3137.5
28,900
Manager TitleAgeSince
Chief Executive Officer 59 01/01/2020
Director of Finance/CFO 50 01/01/2020
Chief Tech/Sci/R&D Officer 59 -
Director TitleAgeSince
Director/Board Member 50 01/01/2020
Director/Board Member 59 01/01/2020
Director/Board Member 44 26/03/2024
Date Insider Type Main position Quantity % Market Cap. Importance
22/4/25 Exercice 50,000 0.4595%
18/4/25 Exercice

Chief Technology Officer

12,500 0.1149%
17/4/25 Exercice

Chief Financial Officer

18,100 0.1663%
Change 5-day change 1-year change 3-year change Capi.($)
+4.22%+2.54%-10.83% - 409M
+0.01%+11.10%+60.83%+70.43% 68.32B
+1.22%+9.56%+15.97%+90.23% 60.26B
+0.24%+1.35%+23.78%+97.55% 55.86B
+1.60%+19.44%+28.80%+112.95% 48.43B
-1.32%+4.78%+29.15%+40.40% 45.34B
-3.54%-0.60%+207.76%+879.50% 41.76B
-3.33%+6.90%+22.78%+48.07% 34.5B
-2.19%-3.71%+90.94%+66.33% 33.8B
-1.69%+0.83%+46.57%-0.16% 25.96B
Average -0.49%+4.83%+51.58%+156.14% 41B
Weighted average by Cap. -0.67%+5.24%+55.24%+153.59%

Financials

2024 2025
Net sales 14.84B 11.04M 9.9M 9.12M 8.29M 15.68M 1.04B 16.12M 109M 43.53M 555M 41.43M 40.55M 1.75B 53.39B 39.72M 35.63M 32.83M 29.82M 56.43M 3.72B 58.01M 393M 157M 2B 149M 146M 6.31B
Net income -8.09B -6.02M -5.4M -4.98M -4.52M -8.55M -565M -8.79M -59.58M -23.74M -302M -22.6M -22.12M -956M 15.78B 11.74M 10.53M 9.71M 8.81M 16.68M 1.1B 17.15M 116M 46.3M 590M 44.07M 43.14M 1.86B
Net Debt -42.69B -31.76M -28.49M -26.25M -23.84M -45.12M -2.98B -46.38M -314M -125M -1.6B -119M -117M -5.04B -52.61B -39.14M -35.1M -32.35M -29.38M -55.6M -3.67B -57.16M -387M -154M -1.97B -147M -144M -6.22B
Projected Income Statement - Annual - Onconic Therapeutics Inc.
Logo Onconic Therapeutics Inc.
Onconic Therapeutics Inc is a Korea-based company principally engaged in the new drugs research and development business. The Company mainly develops new drugs and treatments in the acid-related diseases, digestive diseases and anticancer fields based on small molecules. The Company’s products include acid-related disease treatment drug Zastaprazan and synthetic lethal deoxyribonucleic acid (DNA) damage repair inhibitor anticancer drug Nesuparib.
Employees
-
Date Price Change Volume
10/11/26 KRW 12,100.00 +4.22% 102,391
09/11/26 KRW 11,610.00 -0.60% 138,774
06/11/26 KRW 11,680.00 -3.23% 186,137
05/11/26 KRW 12,070.00 -0.49% 160,135
04/11/26 KRW 12,130.00 +2.80% 163,334
  1. Stock Market
  2. Stocks
  3. A476060 Stock